What is the recommended management of community‑acquired pneumonia in adults, including outpatient, inpatient, and intensive‑care treatment regimens?

Community-Acquired Pneumonia Management in Adults

The management of community-acquired pneumonia (CAP) in adults follows a severity-stratified approach: outpatients without comorbidities receive a macrolide or doxycycline; outpatients with comorbidities receive a respiratory fluoroquinolone OR a β-lactam plus macrolide; hospitalized non-ICU patients receive a respiratory fluoroquinolone OR a β-lactam plus macrolide; and ICU patients require a β-lactam plus either azithromycin or a fluoroquinolone. 1

Outpatient Management

Previously Healthy Patients (No Comorbidities)

• Macrolide (azithromycin, clarithromycin, or erythromycin) - strong recommendation 1
• Doxycycline - acceptable alternative 1

Patients with Comorbidities or Risk Factors

Comorbidities include chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancies; asplenia; immunosuppression; or recent antibiotic use (within 3 months):

• Respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750 mg) - strong recommendation 1
• β-lactam PLUS macrolide - strong recommendation 1
  • Preferred β-lactams: high-dose amoxicillin (1 g three times daily) or amoxicillin-clavulanate (2 g twice daily)
  • Alternatives: ceftriaxone, cefpodoxime, cefuroxime (500 mg twice daily)
  • Doxycycline can substitute for the macrolide

Critical caveat: In regions with high macrolide resistance (≥25% with MIC ≥16 mg/mL for S. pneumoniae), use the combination therapy or fluoroquinolone even in previously healthy patients 1.

Inpatient Non-ICU Management

Two equally effective options:

• Respiratory fluoroquinolone (strong recommendation, level I evidence) 1
• β-lactam PLUS macrolide (strong recommendation, level I evidence) 1
  • Preferred β-lactams: cefotaxime, ceftriaxone, or ampicillin
  • Ertapenem for patients with risk factors for gram-negative pathogens (excluding Pseudomonas)
  • Doxycycline can substitute for the macrolide
  • For penicillin-allergic patients: use respiratory fluoroquinolone

ICU/Severe CAP Management

Standard Severe CAP

β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either:

• Azithromycin (level II evidence), OR
• Fluoroquinolone (level I evidence)
• Strong recommendation 1

For penicillin-allergic patients: respiratory fluoroquinolone plus aztreonam 1

Risk Factors for Pseudomonas aeruginosa

Use antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) PLUS:

• Ciprofloxacin or levofloxacin (750 mg), OR
• Aminoglycoside PLUS azithromycin, OR
• Aminoglycoside PLUS antipneumococcal fluoroquinolone

For penicillin allergy: substitute aztreonam for β-lactam 1

Suspected CA-MRSA

Add vancomycin or linezolid (moderate recommendation) 1

Antibiotic Duration

Minimum 5 days of therapy (level I evidence), with the following criteria met before discontinuation 1:

• Afebrile for 48-72 hours
• No more than 1 CAP-associated sign of clinical instability

Important update: Recent 2025 guidelines suggest shorter durations (minimum 3 days) may be acceptable for outpatients and non-severe hospitalized CAP patients who reach clinical stability, though the traditional 5-day minimum remains standard for severe CAP 2, 3.

Longer therapy is needed if initial therapy was inactive against the identified pathogen or if complicated by extrapulmonary infection (meningitis, endocarditis) 1.

Transition and Discharge Criteria

IV to Oral Switch

Switch when patients are:

• Hemodynamically stable
• Clinically improving
• Able to ingest medications
• Have normally functioning GI tract
• Strong recommendation, level II evidence 1

Discharge immediately after oral switch - inpatient observation while on oral therapy is unnecessary 1.

Timing of First Dose

For ED admissions: administer first antibiotic dose while still in the ED (moderate recommendation) 1.

Special Considerations

Influenza-Associated Pneumonia

For suspected H5N1 or severe influenza with bacterial superinfection:

• Oseltamivir (level II evidence)
• Antibacterials targeting S. pneumoniae and S. aureus 1

Corticosteroids

2025 guidelines recommend:

• May use in severe CAP (within 36 hours of admission)
• Recommend against in non-severe CAP 2, 3

This represents a nuanced update from earlier practice, with corticosteroids showing benefit in reducing ARDS risk and treatment duration in severe cases but not recommended routinely 4.

Pathogen-Directed Therapy

Once etiology is identified through reliable microbiological methods, narrow therapy to target the specific pathogen (moderate recommendation) 1.

Common Pitfalls to Avoid

1. Don't use macrolide monotherapy in hospitalized patients or those with comorbidities - resistance rates make this inadequate
2. Don't delay antibiotics in admitted patients - first dose should be given in the ED
3. Don't continue IV therapy once patients meet oral switch criteria - this unnecessarily prolongs hospitalization
4. Don't forget to assess for Pseudomonas risk factors in ICU patients (structural lung disease, recent hospitalization, recent broad-spectrum antibiotics)
5. Don't overlook local resistance patterns - adjust empiric therapy based on regional macrolide resistance rates

The evidence strongly supports combination therapy for severe CAP, with multiple studies demonstrating improved mortality outcomes compared to monotherapy 1. The IDSA/ATS guidelines remain the cornerstone of CAP management, with recent updates refining antibiotic duration and corticosteroid use 2, 3.